Skip to content
10-Q

Quarterly Report

Solid Biosciences Inc. SLDB

0000950170-24-122247

← back to feed
Filed
Nov 6, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 1, 2024 39.95M sh
Current Liabilities Q3 2024 · Sep 30, 2024 $22.85M
Current Liabilities Q3 2024 · Dec 31, 2023 $14.52M
Total Liabilities Q3 2024 · Sep 30, 2024 $44.8M
Total Liabilities Q3 2024 · Dec 31, 2023 $38.46M
Current Assets Q3 2024 · Sep 30, 2024 $179.49M
Current Assets Q3 2024 · Dec 31, 2023 $129.73M
Total Assets Q3 2024 · Sep 30, 2024 $211.83M
Total Assets Q3 2024 · Dec 31, 2023 $164.94M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $74.02M
Cash And Equivalents Q3 2024 · Sep 30, 2023 $49.04M
Shares Diluted Q3 2024 · Sep 30, 2023 20.06M sh
Shares Diluted Q3 2024 · Sep 30, 2023 19.77M sh
Capex Q3 2024 · Sep 30, 2023 $1.43M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$73.36M
Stockholders Equity Q3 2024 · Sep 30, 2023 $144.36M
Stockholders Equity Q3 2024 · Jun 30, 2023 $163.73M
Stockholders Equity Q3 2024 · Mar 31, 2023 $183.79M
Stockholders Equity Q3 2024 · Dec 31, 2022 $211.67M
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.05
Eps Diluted Q3 2024 · Sep 30, 2023 −$3.83
Eps Basic Q3 2024 · Sep 30, 2023 −$1.05
Eps Basic Q3 2024 · Sep 30, 2023 −$3.83
Sga Expense Q3 2024 · Sep 30, 2023 $6.41M
Sga Expense Q3 2024 · Sep 30, 2023 $20.94M
Rd Expense Q3 2024 · Sep 30, 2023 $16.7M
Rd Expense Q3 2024 · Sep 30, 2023 $61.11M
Operating Income Q3 2024 · Sep 30, 2023 −$23.11M
Operating Income Q3 2024 · Sep 30, 2023 −$81.99M